» Articles » PMID: 4205945

Development of a Purified Cholera Toxoid. I. Purification of Toxin

Overview
Journal Infect Immun
Date 1974 Feb 1
PMID 4205945
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

The enterotoxin from Vibrio cholerae is selectively concentrated from cell-free culture supernatant by co-precipitation with hexametaphosphate and is further purified by adsorption on aluminum hydroxide powder. The bulk of residual somatic antigen becomes insoluble upon lyophilization of the toxin preparation and is removed by centrifugation of the rehydrated material. Other contaminants are eliminated by treatment with activated carbon. Preparations of toxin, purified by this method, have been characterized by: (i) a single immunoprecipitin line against polyvalent antisera; (ii) homogeneity on acrylamide gels; (iii) specific activities on the order of 22 limit-of-bluing doses/mug; (iv) ultraviolet spectra characteristic of pure protein; and (v) overall yields on the order of 50%, irrespective of purification scale. Such preparations, however, have been shown to contain trace amounts of somatic antigen when they are intensively tested either for their ability to elevate serum vibriocidal antibody titers in immunized rabbits or for their ability to increase resistance of immunized mice to live vibrio challenge. In the latter test system, the level of residual somatic antigen per 50 mug of toxin (toxoid) antigen generally did not exceed 0.025% of the Division of Biological Standards reference vaccine, V. cholerae Inaba IN-12. Methods for elimination of this small amount of somatic antigen have been investigated and are discussed. The particular combination of purification steps which are presently described have been easily and reproducibly applied on a production scale to prepare gram amounts of toxin with a high degree of purity, even under a variety of initial conditions.

Citing Articles

Neuregulin-1 at synapses on phrenic motoneurons.

Issa A, Zhan W, Sieck G, Mantilla C J Comp Neurol. 2010; 518(20):4213-25.

PMID: 20878784 PMC: 2948240. DOI: 10.1002/cne.22449.


Cholera toxin B subunit activates arachidonic acid metabolism.

Peterson J, Finkelstein R, Cantu J, Gessell D, Chopra A Infect Immun. 1999; 67(2):794-9.

PMID: 9916092 PMC: 96388. DOI: 10.1128/IAI.67.2.794-799.1999.


A nontoxic cholera enterotoxin (CT) analog is chimeric with regard to both epitypes of CT-B subunits, CT-B-1 and CT-B-2.

Peterson J, Thai L, Finkelstein R Infect Immun. 1996; 64(1):346-8.

PMID: 8557362 PMC: 173766. DOI: 10.1128/iai.64.1.346-348.1996.


Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

Fontana M, Manetti R, Giannelli V, Magagnoli C, Marchini A, Olivieri R Infect Immun. 1995; 63(6):2356-60.

PMID: 7768621 PMC: 173311. DOI: 10.1128/iai.63.6.2356-2360.1995.


Lincomycin increases synthetic rate and periplasmic pool size for cholera toxin.

Levner M, Urbano C, RUBIN B J Bacteriol. 1980; 143(1):441-7.

PMID: 7400099 PMC: 294266. DOI: 10.1128/jb.143.1.441-447.1980.


References
1.
Richardson S . Factors influencing in vitro skin permeability factor production by Vibrio cholerae. J Bacteriol. 1969; 100(1):27-34. PMC: 315353. DOI: 10.1128/jb.100.1.27-34.1969. View

2.
Craig J . Preparation of the vascular permeability factor of Vibrio cholerae. J Bacteriol. 1966; 92(3):793-5. PMC: 276327. DOI: 10.1128/jb.92.3.793-795.1966. View

3.
Davis B . DISC ELECTROPHORESIS. II. METHOD AND APPLICATION TO HUMAN SERUM PROTEINS. Ann N Y Acad Sci. 1964; 121:404-27. DOI: 10.1111/j.1749-6632.1964.tb14213.x. View

4.
Pierce N, Kaniecki E, Northrup R . Protection against experimental cholera by antitoxin. J Infect Dis. 1972; 126(6):606-16. DOI: 10.1093/infdis/126.6.606. View

5.
MUSCHEL L, TREFFERS H . Quantitative studies on the bactericidal actions of serum and complement. I. A rapid photometric growth assay for bactericidal activity. J Immunol. 1956; 76(1):1-10. View